Sujal Shah
2022
In 2022, Sujal Shah earned a total compensation of $2.6M as Chief Executive Officer at Cymabay Therapeutics, a 16% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $450,000 |
|---|---|
| Option Awards | $1,518,010 |
| Salary | $590,000 |
| Other | $3,773 |
| Total | $2,561,783 |
Shah received $1.5M in option awards, accounting for 59% of the total pay in 2022.
Shah also received $450K in non-equity incentive plan, $590K in salary and $3.8K in other compensation.
Rankings
In 2022, Sujal Shah's compensation ranked 1,417th out of 5,753 executives tracked by ExecPay. In other words, Shah earned more than 75.4% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,417 out of 5,753 | 75th |
Division Manufacturing | 707 out of 3,133 | 77th |
Major group Chemicals And Allied Products | 271 out of 1,419 | 81st |
Industry group Drugs | 250 out of 1,320 | 81st |
Industry Pharmaceutical Preparations | 176 out of 966 | 82nd |
Source: SEC filing on April 19, 2023.
Shah's colleagues
We found two more compensation records of executives who worked with Sujal Shah at Cymabay Therapeutics in 2022.
News
Cymabay Therapeutics CEO Sujal Shah's 2022 pay rises 16% to $2.6M
April 19, 2023
Cymabay Therapeutics CEO Sujal Shah's 2021 pay slips 16% to $2.2M
April 26, 2022
Cymabay Therapeutics CEO Sujal Shah's 2019 pay jumps 32% to $2.6M
May 15, 2020
Cymabay Therapeutics General Counsel Paul Quinlan receives $3M in 2018
April 26, 2019